1 / 8

Featured Article :

Featured Article :. Safety of Outpatient Closed-Loop Control: First Randomized Crossover Trials of a Wearable Artificial Pancreas. Boris P. Kovatchev, Eric Renard, Claudio Cobelli, Howard C. Zisser,

stacy
Download Presentation

Featured Article :

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Featured Article: Safety of Outpatient Closed-Loop Control: First Randomized Crossover Trials of a Wearable Artificial Pancreas Boris P. Kovatchev, Eric Renard, Claudio Cobelli, Howard C. Zisser, Patrick Keith-Hynes, Stacey M. Anderson, Sue A. Brown, Daniel R. Chernavvsky, Marc D. Breton, Lloyd B. Mize, Anne Farret, Jérôme Place, Daniela Bruttomesso, Simone Del Favero, Federico Boscari, Silvia Galasso, Angelo Avogaro, Lalo Magni, Federico Di Palma, Chiara Toffanin, Mirko Messori, Eyal Dassau, and Francis J. Doyle III Diabetes Care Volume 37: 1789-1797 July, 2014

  2. STUDY OBJECTIVE • To estimate the effect size of hypoglycemia risk reduction on closed-loop control (CLC) versus open-loop (OL) sensor-augmented insulin pump therapy in a supervised outpatient setting Kovatchev B. P. et al. Diabetes Care 2014;37:1789-1797

  3. STUDY DESIGN AND METHODS • 20 patients with type 1 diabetes initiated the study at the Universities of Virginia, Padova, and Montpellier and Sansum Diabetes Research Institute • 18 completed the entire protocol • Each patient participated in two 40-h outpatient sessions, CLC versus OL, in randomized order • Sensor (Dexcom G4) and insulin pump (Tandem t:slim) were connected to Diabetes Assistant (DiAs) (a smartphone artificial pancreas platform) Kovatchev B. P. et al. Diabetes Care 2014;37:1789-1797

  4. STUDY DESIGN AND METHODS • The patient operated the system through the DiAs user interface during both CLC and OL • Study personnel supervised onsite and monitored DiAs remotely Kovatchev B. P. et al. Diabetes Care 2014;37:1789-1797

  5. RESULTS • The primary outcome [reduction in risk for hypoglycemia as measured by the low • blood glucose (BG) index (LGBI)] resulted in an effect size of 0.64 • There was a twofold reduction of hypoglycemia requiring carbohydrate treatment: 1.2 vs. 2.4 episodes/session on CLC versus OL • This result was accompanied by a slight decrease in percentage of time in the target range of 3.9–10 mmol/L and increase in mean BG on CLC versus OL Kovatchev B. P. et al. Diabetes Care 2014;37:1789-1797

  6. Kovatchev B. P. et al. Diabetes Care 2014;37:1789-1797

  7. Kovatchev B. P. et al. Diabetes Care 2014;37:1789-1797

  8. CONCLUSIONS • CLC running on a smartphone (DiAs) in outpatient conditions reduced hypoglycemia and hypoglycemia treatments compared with sensor-augmented pump therapy Kovatchev B. P. et al. Diabetes Care 2014;37:1789-1797

More Related